Cannabis Culture in Congress: Lawmakers, Legislation, and Personal Use

Executive Summary

Cannabis use among members of Congress has evolved from a taboo subject to an increasingly open topic of discussion, reflecting broader shifts in American attitudes toward marijuana. Representative Ilhan Omar's May 2026 statement that she believes "a lot of people" in Congress smoke marijuana represents the latest acknowledgment of what many Capitol Hill observers have long suspected: lawmakers are not immune to the cultural normalization of cannabis consumption sweeping the United States. This topic encompasses the personal cannabis use habits of federal legislators, the apparent disconnect between congressional consumption and federal prohibition, the impact of lawmaker attitudes on cannabis policy reform, and the evolving culture around marijuana within the halls of power. As 38 states have legalized medical marijuana and 24 states permit adult-use cannabis as of May 2026, the gap between state-level acceptance and federal Schedule I classification under the Controlled Substances Act creates a unique tension for members of Congress who may personally use a substance their institution continues to criminalize at the federal level.

Why This Matters

The personal cannabis consumption habits of federal lawmakers directly influence the trajectory of national drug policy affecting millions of Americans and a legal cannabis industry valued at over $33 billion annually. When members of Congress use marijuana—whether for medical purposes, recreational enjoyment, or both—their firsthand experience potentially shapes their legislative priorities, voting patterns, and willingness to challenge decades of prohibition.

For the estimated 55 million American adults who used cannabis in 2025, congressional attitudes matter immensely. Federal prohibition continues to create banking obstacles through the lack of SAFE Banking Act passage, prevents interstate commerce, maintains the punitive Internal Revenue Code Section 280E tax burden on cannabis businesses, and perpetuates criminal records that disproportionately affect communities of color. Patient stakeholders—particularly the approximately 6 million registered medical marijuana patients nationwide—depend on congressional action to expand research access, protect state programs from federal interference, and potentially reschedule or deschedule cannabis entirely.

The cannabis industry watches congressional culture closely because personal use among lawmakers correlates with policy support. Operators, investors, and multi-state operators face continued uncertainty around federal enforcement priorities, tax treatment, and the possibility of interstate commerce. A Congress that includes members who personally consume cannabis is theoretically more likely to advance comprehensive reform, though the relationship between personal use and legislative action remains complex and often contradictory.

Background and History: Cannabis on Capitol Hill

The relationship between Congress and cannabis has transformed dramatically over seven decades, from the architects of prohibition to a body where open discussion of personal use is no longer career-ending.

The Prohibition Architects (1937-1970)

Congress established the foundation for federal cannabis prohibition with the Marihuana Tax Act of 1937, which effectively criminalized possession and sale through prohibitive taxation. The legislative debate featured testimony characterized by racial prejudice and unsubstantiated claims about cannabis-induced violence. For the next three decades, no member of Congress publicly questioned this framework, and personal use was unthinkable for federal lawmakers whose careers depended on projecting moral authority during the height of American social conservatism.

The Controlled Substances Act of 1970, enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act, placed marijuana in Schedule I alongside heroin, defining it as having no accepted medical use and high potential for abuse. Congress passed this classification despite the pending recommendations of the Shafer Commission, which President Nixon had appointed to study marijuana. When the commission recommended decriminalization in 1972, Congress ignored the findings, cementing a prohibitionist stance that would persist for decades.

The First Cracks in Consensus (1970s-1990s)

The 1970s saw the first congressional voices questioning absolute prohibition, though none admitted personal use. Representative Koch of New York and a handful of others supported decriminalization bills that went nowhere. The Reagan era's "Just Say No" campaign and the 1986 Anti-Drug Abuse Act—which created mandatory minimum sentences for drug offenses including cannabis—represented Congress at its most punitive. During this period, any suggestion of personal cannabis use would have ended a political career immediately.

The 1996 passage of California's Proposition 215, establishing the nation's first comprehensive medical marijuana program, created the first major tension between state law and federal prohibition. Congress responded not with acceptance but with increased enforcement rhetoric. The Congressional response included threats to prosecute California physicians who recommended cannabis and efforts to override the voter initiative through federal preemption.

Medical Marijuana and Shifting Attitudes (2000-2012)

As more states adopted medical marijuana programs throughout the 2000s, congressional attitudes began a gradual shift. The Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer), first passed in 2014 but debated for years prior, prohibited the Department of Justice from using funds to prevent states from implementing their own medical cannabis laws. This represented a significant policy evolution, though it fell short of removing federal prohibition.

Representative Ron Paul of Texas introduced multiple bills to end federal marijuana prohibition during his tenure, arguing from a states' rights perspective. While Paul never publicly acknowledged personal use, his willingness to challenge prohibition openly signaled changing political calculations around cannabis advocacy. By 2012, when Colorado and Washington became the first states to legalize adult-use cannabis, the congressional conversation had shifted from whether medical marijuana had legitimacy to whether adult-use legalization could coexist with federal law.

The Modern Era of Openness (2013-Present)

The Obama administration's 2013 Cole Memorandum, which deprioritized federal enforcement in states with legal cannabis programs, emboldened congressional reformers. Representative Earl Blumenauer of Oregon emerged as a leading cannabis advocate, founding the Congressional Cannabis Caucus in 2017 alongside Representatives Jared Polis, Dana Rohrabacher, and Don Young. While caucus members advocated for reform, public acknowledgment of personal use remained rare.

The first significant public admission came in 2019 when Representative Alexandria Ocasio-Cortez acknowledged past cannabis use during a discussion of criminal justice reform. Her statement—made without apparent political consequence—marked a generational shift. By 2020, multiple members of Congress had acknowledged past use, and the question shifted from "have you ever" to "do you currently."

The 2020 House passage of the MORE Act, which would deschedule cannabis and expunge federal convictions, represented a historic milestone despite Senate inaction. The 228-164 vote demonstrated that cannabis reform had moved from fringe to mainstream within at least one chamber of Congress. The Senate's failure to act highlighted the remaining generational and ideological divide.

The Omar Statement and Current Context (2024-2026)

Representative Ilhan Omar's May 2026 statement that she believes "a lot of people" in Congress smoke marijuana represents the latest evolution in this trajectory. Unlike earlier admissions of past use, Omar's comment suggests ongoing consumption among current members—a claim that would have been scandalous a decade earlier but now generates headlines without calls for resignation. The statement came during a broader discussion of cannabis policy reform and the disconnect between federal law and state-level legalization.

As of May 2026, Congress has yet to pass comprehensive cannabis reform despite multiple bills including the rescheduling recommendations from the Department of Health and Human Services in 2023 and the Drug Enforcement Administration's ongoing review process. The cultural acceptance of cannabis use among members has outpaced legislative action, creating a peculiar situation where lawmakers may personally consume a federally illegal substance while debating its legal status.

Key Players in Congressional Cannabis Culture

Legislative Champions

Representative Earl Blumenauer (D-OR) has served as Congress's most visible cannabis advocate since the mid-2010s. Blumenauer founded the Congressional Cannabis Caucus and has introduced numerous reform bills including measures to address 280E taxation, banking access, and veterans' access to medical marijuana. While Blumenauer has not publicly acknowledged personal use, his district includes Portland, Oregon, a city with deeply embedded cannabis culture, and his advocacy reflects constituent values.

Senate Majority Leader Chuck Schumer (D-NY) evolved from cannabis skeptic to reform advocate, introducing the Cannabis Administration and Opportunity Act in 2022. Schumer's shift reflected changing attitudes in New York, which legalized adult-use cannabis in 2021. His leadership position makes his support crucial for any Senate action, though he has not acknowledged personal use.

Representative Alexandria Ocasio-Cortez (D-NY) represents a younger generation of lawmakers who came of age during shifting cannabis attitudes. Her 2019 acknowledgment of past use and continued advocacy for legalization as a criminal justice issue has helped normalize discussion of personal experience with cannabis among members of Congress.

Opposition Voices

Senator Tom Cotton (R-AR) remains one of Congress's most vocal cannabis opponents, arguing that legalization would increase youth use and impaired driving. Cotton has blocked multiple reform bills in the Senate and represents a conservative faction that views federal prohibition as a moral and public safety imperative. His opposition is rooted in traditional drug war ideology rather than personal experience.

Representative Andy Harris (R-MD), an anesthesiologist by training, has used his position on the House Appropriations Committee to block cannabis reform in the District of Columbia and oppose broader legalization efforts. Harris argues from a medical perspective that cannabis poses health risks, though critics note the contradiction of his support for alcohol and tobacco regulation versus cannabis prohibition.

The Congressional Cannabis Caucus

Founded in 2017, the bipartisan Congressional Cannabis Caucus includes over 30 members as of 2026. The caucus serves as a forum for education and advocacy around cannabis policy reform, hosting briefings on topics from banking to medical research. While membership does not require acknowledgment of personal use, the caucus has helped normalize cannabis discussion within Congress and provided political cover for members from conservative districts to support reform measures.

Generational Divide

The most significant player in congressional cannabis culture may be generational turnover itself. Members of Congress born after 1970—who came of age during the early medical marijuana movement—show markedly different attitudes toward cannabis than their predecessors. Polling data from 2025 showed that 78% of Americans under 50 support legalization, compared to 52% of those over 65. As younger members replace retiring prohibitionists, the cultural acceptance of cannabis within Congress accelerates regardless of individual consumption habits.

Legal and Regulatory Framework

Members of Congress operate under the same federal cannabis prohibition that applies to all Americans, creating a legal paradox when lawmakers consume a Schedule I controlled substance.

The Controlled Substances Act

Under 21 U.S.C. § 812, marijuana remains a Schedule I controlled substance, defined as having high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Possession, distribution, and cultivation remain federal crimes under 21 U.S.C. § 841, with penalties ranging from misdemeanors for small amounts to felonies for larger quantities or distribution.

Congress members who consume cannabis in states with legal programs technically violate federal law, though prosecution is extraordinarily unlikely given the separation of powers and the political implications of charging a sitting member of Congress with marijuana possession. The Cole Memorandum and subsequent enforcement guidance have deprioritized individual users in legal states, but this policy discretion offers no legal protection—merely practical immunity.

Congressional Privilege and Immunity

The Speech or Debate Clause of the Constitution (Article I, Section 6, Clause 1) protects members of Congress from arrest during attendance at sessions and while traveling to and from Congress, except for "Treason, Felony and Breach of the Peace." Historical interpretation suggests that drug possession could constitute a felony or breach of peace, potentially falling outside this protection. However, no modern precedent exists for arresting a member of Congress for marijuana possession, making the practical application of these constitutional provisions unclear.

Members of Congress are not subject to random drug testing, unlike many federal employees and military personnel. Congressional staff may face different standards depending on their positions and security clearances, but members themselves operate under self-governance through ethics rules rather than executive branch employment policies.

State Law Complications

Members of Congress who maintain residences in states with legal cannabis programs can legally purchase and possess marijuana under state law. Washington, D.C., where Congress conducts its business, legalized possession and home cultivation through Initiative 71 in 2014, though commercial sales remain prohibited due to congressional interference through appropriations riders. This creates a situation where members could legally possess cannabis in both their home states and the nation's capital under local law while violating federal statutes they have the power to amend.

The Supremacy Clause (Article VI, Clause 2) establishes that federal law supersedes conflicting state law, meaning state legalization provides no defense to federal prosecution. However, the anti-commandeering doctrine prevents the federal government from requiring states to enforce federal marijuana prohibition, creating the current patchwork of state-legal, federally-illegal cannabis programs.

Ethics and Disclosure Requirements

Congressional ethics rules do not specifically address cannabis use, focusing instead on financial conflicts of interest, gift acceptance, and official conduct. Members who invest in cannabis companies must disclose these holdings under the STOCK Act, and several members have faced scrutiny for trading cannabis stocks while voting on related legislation. Personal use, however, falls outside current ethics disclosure requirements, treated as a private matter unless it affects official duties or involves criminal conduct beyond simple possession.

The Culture Gap: Personal Use vs. Legislative Action

A significant disconnect exists between the apparent personal cannabis acceptance among members of Congress and the institution's failure to enact comprehensive federal reform. This gap reflects political calculation, constituent pressure, and the structural obstacles of the legislative process rather than simple hypocrisy.

Members from conservative districts who may personally support reform or even consume cannabis face electoral consequences for public advocacy. The Senate's composition, which overrepresents rural states where cannabis opposition remains stronger, creates a structural barrier to reform even as House members from urban districts push legalization bills. The filibuster requirement of 60 votes for most Senate legislation makes comprehensive reform nearly impossible without bipartisan consensus that does not yet exist.

Additionally, personal consumption does not necessarily translate to support for full legalization. Some members who use cannabis may support medical programs or decriminalization while opposing commercial adult-use markets. Others may view their personal use as a private matter separate from their policy positions, maintaining a distinction between individual liberty and federal regulatory frameworks.

What Experts and Observers Say

Political analysts and cannabis policy experts have offered varied interpretations of congressional cannabis culture and its policy implications.

According to Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws (NORML), the increasing openness about cannabis use among members of Congress reflects broader societal shifts. Fox noted in a 2025 interview that personal experience with cannabis can humanize the issue and counter decades of prohibition propaganda, though he cautioned that individual consumption does not guarantee legislative support for reform.

Kevin Sabet, president of Smart Approaches to Marijuana (SAM) and a legalization opponent, has argued that casual cannabis use among lawmakers undermines the seriousness of drug policy debates. Sabet contends that members of Congress should model abstinence from federally illegal substances regardless of state law, and that personal use creates conflicts of interest when voting on cannabis legislation.

Political scientist John Hudak of the Brookings Institution has researched congressional attitudes toward cannabis and found that generational replacement drives policy change more than individual conversion. According to Hudak's analysis, members who entered Congress after 2010 show dramatically higher support for legalization than those elected before 2000, suggesting that cultural attitudes formed before entering office matter more than Capitol Hill socialization.

Representative Earl Blumenauer has stated publicly that he believes cannabis use among members of Congress is more common than most Americans realize, though he has declined to name specific colleagues or acknowledge his own use. Blumenauer argues that the normalization of cannabis discussion within Congress is essential for policy reform, as it breaks down the stigma that has prevented rational drug policy for decades.

Cannabis industry analysts view congressional culture as a lagging indicator of broader social change rather than a leading force for reform. Emily Paxhia, co-founder of Poseidon Investment Management, noted in a 2026 industry conference that while personal use among lawmakers is encouraging, the industry needs concrete legislative action on banking, taxation, and interstate commerce rather than cultural acceptance alone.

Market and Business Implications

The cannabis industry's trajectory depends significantly on congressional action, making the culture and attitudes of federal lawmakers a material business concern for operators and investors.

The legal cannabis market generated approximately $33.6 billion in sales in 2025, with projections reaching $50 billion by 2028 under current state-level legalization trends. However, federal prohibition creates substantial obstacles that congressional action could remove or perpetuate. The lack of SAFE Banking Act passage forces many cannabis businesses to operate on a cash basis, increasing security costs and limiting access to traditional financial services including business loans, credit card processing, and bank accounts.

Internal Revenue Code Section 280E, which prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, creates effective tax rates of 70% or higher for cannabis operators. This tax burden—which Congress could eliminate through legislation or which would disappear automatically if the DEA reschedules cannabis to Schedule III or below—represents one of the industry's most significant federal policy obstacles. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have identified 280E reform as a top legislative priority, as it directly impacts profitability and competitive positioning.

Congressional culture affects these business concerns because personal cannabis use among members theoretically increases the likelihood of reform. However, the relationship is not straightforward. Some members who support cannabis businesses come from states with legal programs and view the industry as an economic development opportunity regardless of personal use. Others who may personally consume cannabis represent districts where commercial cultivation and sales remain controversial, limiting their ability to advocate publicly for industry-friendly policies.

The investment community watches congressional signals closely. Institutional investors remain largely sidelined from U.S. cannabis markets due to federal prohibition, with major banks and investment firms prohibited from holding positions in companies that violate federal law. Congressional movement toward legalization or rescheduling could unlock billions in institutional capital, dramatically changing industry capitalization and consolidation patterns. Conversely, continued federal prohibition limits the industry to smaller investors, high-net-worth individuals, and Canadian institutional players willing to accept U.S. regulatory risk.

Interstate commerce represents another major business implication of congressional action. Current federal prohibition prevents cannabis from crossing state lines, forcing multi-state operators to build duplicative cultivation and processing facilities in each state where they operate. This inefficiency increases costs and limits economies of scale. Congressional legalization that permitted interstate commerce would fundamentally restructure the industry, likely concentrating production in states with favorable growing conditions and lower costs such as California, Oregon, and Oklahoma.

What's Next: The Path Forward

The trajectory of congressional cannabis culture and policy depends on several near-term developments and longer-term structural factors.

DEA Rescheduling Decision (2026)

The Drug Enforcement Administration's ongoing review of cannabis scheduling, initiated by the Department of Health and Human Services' August 2023 recommendation to move marijuana to Schedule III, represents the most immediate policy catalyst. A final decision is expected by late 2026 or early 2027. Rescheduling to Schedule III would not legalize cannabis but would eliminate 280E tax burdens and acknowledge accepted medical use, potentially shifting congressional attitudes by reducing the gap between federal classification and scientific consensus.

2026 Midterm Elections

The November 2026 midterm elections will determine congressional composition for the final two years of the current presidential term. Several states including Florida, Ohio, and Pennsylvania have cannabis legalization measures on the ballot, and outcomes will influence the political calculus for members from those states. Additionally, retirements among older, prohibition-supporting members and their replacement with younger candidates could accelerate the cultural shift within Congress.

Pending Legislation

Multiple cannabis reform bills remain in various stages of the legislative process as of May 2026. The SAFE Banking Act has passed the House multiple times but faces Senate obstacles. The Cannabis Administration and Opportunity Act, introduced by Senator Schumer, would deschedule cannabis and establish a federal regulatory framework but lacks the votes for passage. More modest measures addressing veterans' access, medical research, and state program protection have better prospects for incremental progress.

Presidential Leadership

The 2024 presidential election results and the administration's enforcement priorities will shape congressional action. A president who actively supports legalization and uses executive authority to deprioritize enforcement can provide political cover for congressional reform. Conversely, an administration that emphasizes drug enforcement could slow momentum despite changing congressional culture.

Long-Term Structural Trends

Generational replacement within Congress will continue regardless of short-term political developments. As members who came of age during absolute prohibition retire and are replaced by those who experienced medical marijuana normalization or adult-use legalization, the baseline assumptions about cannabis policy will shift. Demographic trends suggest that by 2030, a majority of Congress will have entered adulthood after California's 1996 medical marijuana initiative, fundamentally changing the cultural context for cannabis discussions.

State-level legalization will also continue to expand, increasing the percentage of Americans living under legal cannabis regimes and the number of congressional districts where cannabis businesses operate and employ constituents. This creates electoral incentives for members to support federal reform to protect state programs and local businesses, independent of personal consumption habits.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.deadiversion.usdoj.gov/21cfr/21usc/
• Congressional Cannabis Caucus official information - https://blumenauer.house.gov/cannabis-caucus
• Drug Enforcement Administration cannabis scheduling docket - https://www.regulations.gov/docket/DEA-2023-0059
• National Organization for the Reform of Marijuana Laws (NORML) congressional scorecard - https://norml.org/congressional-scorecard/
• Marijuana Policy Project federal legislation tracker - https://www.mpp.org/issues/legislation/federal/
• Congressional Research Service reports on cannabis policy - https://crsreports.congress.gov/
• The Hill's cannabis policy coverage archive - https://thehill.com/policy/healthcare/
• Brookings Institution cannabis policy research - https://www.brookings.edu/topic/marijuana/
• U.S. House Roll Call Votes on cannabis legislation - https://clerk.house.gov/Votes
• Senate Judiciary Committee cannabis hearing records - https://www.judiciary.senate.gov/